This is a proposal to study the cellular and biochemical mechanism of the myeloma tumor cell suppression mediated by the host isotype-specific suppressor T cells with Fc receptors that are found in mice and patients with multiple myeloma. We have previously shown that mice and patients with multiple myeloma develop an extraordinary increase in circulating T cells with surface receptors for the Fc portion of immunoglobulin molecules. In addition, we have shown that these Fc receptor-bearing T cells are isotype-specific suppressor cells in normal immune response models. Recent studies have shown that T cells with IgA-Fc receptors, acting through a soluble factor, can suppress both the growth and secretion of IgA myeloma tumor cells. Since the exact mechanism of this suppression is unknown, we herein propose to utilize an IgA murine myeloma model to: 1) establish if T cell-T cell or T cell-macrophage interactions are necessary for this response, 2) establish if the major histocompatibility gene complex or the immunoglobulin heavy chain gene complex are important in controlling this response, 3) characterize biochemically the soluble suppressor factor produced by T cells with IgA-Fc receptors and, 4) characterize the kinetics and biochemical events associated with myeloma cell suppression. In addition, in order to establish the generality of this response,we will extend out studies with murine IgA myeloma to study: 5) the effects of Fc-receptor-bearing T cells on IgG and IgM murine myeloma, and 6) the effects of Fc-receptor-bearing T cells on human myeloma tumor cells in vitro. Since Fc-receptor-bearing T cells can suppress myeloma tumor cell growth, information obtained from the above proposed studies might ultimately be exploited clinically in the treatment of patients with multiple myeloma or other tumors of B cell origin, such as leukemia or lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA041165-01
Application #
3181435
Study Section
Immunobiology Study Section (IMB)
Project Start
1986-04-15
Project End
1989-03-31
Budget Start
1986-04-15
Budget End
1987-03-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Grigorieva, I; Grigoriev, V G; Rowney, M K et al. (2000) Regulation of c-myc transcription by interleukin-2 (IL-2). Identification of a novel IL-2 response element interacting with STAT-4. J Biol Chem 275:7343-50
Hoover, R G; Lary, C; Page, R et al. (1995) Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest 95:241-7
Epstein, J; Hoover, R; Kornbluth, J et al. (1995) Biological aspects of multiple myeloma. Baillieres Clin Haematol 8:721-34
Moore, J S; Hoover, R G (1989) Defective isotype-specific regulation of IgA anti-erythrocyte autoantibody-forming cells in NZB mice. J Immunol 142:4282-8
Moore, J S; Prystowsky, M B; Hoover, R G et al. (1988) Defective T cell-mediated, isotype-specific immunoglobulin regulation in B cell chronic lymphocytic leukemia. Blood 71:1012-20
Kornbluth, J; Hoover, R G (1988) Changes in gene expression associated with IFN-beta and IL-2-induced augmentation of human natural killer cell function. J Immunol 141:3234-40
Roman, S; Moore, J S; Darby, C et al. (1988) Modulation of Ig gene expression by Ig binding factors. Suppression of alpha-H chain and lambda-2-L chain mRNA accumulation in MOPC-315 by IgA-binding factor. J Immunol 140:3622-30
Sukhatme, V P; Kartha, S; Toback, F G et al. (1987) A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res 1:343-55
Broome, H E; Reed, J C; Godillot, E P et al. (1987) Differential promoter utilization by the c-myc gene in mitogen- and interleukin-2-stimulated human lymphocytes. Mol Cell Biol 7:2988-93